Addition of losartan to FOLFIRINOX and chemoradiation reduces immunosuppression-associated genes, Tregs and FOXP3+ cancer cells in locally advanced pancreatic cancer.
Yves BoucherJessica M PosadaSonu SubudhiAshwin Srinivasan KumarSpencer R RosarioLiqun GuHeena KumraMari A Mino-KenudsonNilesh P TaleleDan G DudaDai FukumuraJennifer Y WoJeffrey W ClarkDavid P RyanCarlos F Fernandez-Del CastilloTheodore S HongMikaël J PittetRakesh K JainPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Adding losartan to FFX+CRT reduced pro-invasion and immunosuppression related genes which were associated with improved OS in patients with LAPC. Lesions from responders in the LOS+FFX+CRT-treated group had reduced Tregs, decreased C-FOXP3 and increased CD8+ T cells. These findings suggest that losartan may potentiate the benefit of FFX+CRT by reducing immunosuppression.
Keyphrases
- locally advanced
- rectal cancer
- cardiac resynchronization therapy
- regulatory t cells
- angiotensin ii
- neoadjuvant chemotherapy
- squamous cell carcinoma
- phase ii study
- radiation therapy
- left ventricular
- heart failure
- genome wide
- cell migration
- dna methylation
- atrial fibrillation
- genome wide identification
- genome wide analysis